Analyst Price Target is $23.00
▲ +10.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $23.00, with a high forecast of $34.00 and a low forecast of $16.00. The average price target represents a 10.21% upside from the last price of $20.87.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Pharvaris. This Buy consensus rating has held steady for over two years.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.